Clinical Trial Update: Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC) [NA]

View source ↗

Summary

A completed clinical trial evaluating ulinastatin to prevent postoperative hepatic failure in hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Ulinastatin (ulinastatin)

Snippet

Sponsor: Eastern Hepatobiliary Surgery Hospital | Conditions: Hepatocellular Carcinoma | NA | Status: COMPLETED